C$0.5 0.0 0.0%
Last Trade - 02/12/19
| Market Cap | £28.7m |
| Enterprise Value | £26.8m |
| Revenue | £n/a |
| Position in Universe | 827th / 2611 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | TTM | 2019E | 2020E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|---|
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2019
|
31st Dec 2020
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Zomedica Pharmaceuticals Corp., formerly Wise Oakwood Ventures Inc., is a veterinary pharmaceutical and healthcare solutions company. The Company's principal business relates to the discovery, development and commercialization of pharmaceuticals for the companion pet. The Company's first product candidate, ZM-012, is a tablet formulation of metronidazole, an anti-infective for the treatment of diarrhea in canines (dogs). The Company's second product candidate, ZM-006, is a transdermal gel that delivers its active pharmaceutical ingredient, methimazole, which is used in veterinary medicine to treat hyperthyroidism in felines (cats). The Company's third product candidate, ZM-007, is an oral suspension formulation of metronidazole for accurate dosing of small dog breeds and puppies. The Company's fourth product candidate, ZM-011 is a transdermal gel of fluoxetine, Prozac, prescribed to treat cat behavioral disorders, such as inappropriate urination.
| Last Annual | December 31st, 2018 |
| Last Interim | September 30th, 2019 |
| Incorporated | January 7, 2013 |
| Public Since | October 28, 2013 |
| No. of Shareholders: | n/a |
| No. of Employees: | 27 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | |
| Exchange | TSX Venture Exchange |
| Shares in Issue | 108,038,398 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 100 Phoenix Dr Ste 190, ANN ARBOR, 48108-2636, United States |
| Web | http://www.zomedica.com/ |
| Phone | +1 734 3692555 |
| Contact | () |
| Auditors | MNP LLP |
